MRVI Maravai LifeSciences
- 8.800
- +0.380+4.51%
- 8.420
- -0.380-4.32%
Maravai LifeSciences News
Craig-Hallum Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)
Express News | TriLink BioTechnologies And Lonza Enter Into Non-exclusive License And Supply Agreement For CleanCap MRNA Capping Technology
Express News | Trilink Biotechnologies: Trilink Will Supply Patented Cleancap Analogs for Use in Lonza's Global Mrna Development and Manufacturing Services
Express News | Trilink Biotechnologies® and Lonza Enter Into Non-Exclusive License and Supply Agreement for Cleancap® Mrna Capping Technology
Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego
Maravai LifeSciences Holdings' (MRVI) TriLink BioTechnologies unit said Thursday that it has opened its new, 32,000-square-foot cGMP mRNA manufacturing facility in San Diego. The facility will use Tri
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Inspire Medical Systems (INSP) and Maravai Lifesciences Holdings (MRVI)
Express News | Trilink Biotechnologies, A Maravai Lifesciences Company Opened A New 32,000 Sq.ft. MRNA Manufacturing Facility
HROW, HCAT and EGRX Are Among After Hour Movers
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
Maravai LifeSciences, Inc.(Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
Express News | Craig-Hallum Initiates Coverage On Maravai LifeSciences With Buy Rating, Announces Price Target of $15
Maravai LifeSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/10/2024 72.61% Craig-Hallum → $15 Initiates Coverage On → Buy 02/23/2024 61.1% RBC Capital $12 → $14 Ma
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday.
RBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)
RBC Raises Price Target on Maravai LifeSciences Holdings to $15 From $14, Keeps Outperform Rating
07:50 AM EDT, 04/08/2024 (MT Newswires) -- RBC Raises Price Target on Maravai LifeSciences Holdings to $15 From $14, Keeps Outperform Rating
Is Maravai LifeSciences Holdings (NASDAQ:MRVI) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved whe
Trending Stocks Today: MicroCloud Hologram Inches up 6.7% Post-Market
April 3rd - US stocks trending post-market.Gainers: $MicroCloud Hologram(HOLO.US)$ up 6.7% to $4.14 with a turnover of $5.87 million. $Intuitive Machines(LUNR.US)$ inches up 5.18% to $6.29 with a turn
Ford, Envista Holdings, and Alaska Air Are Among Additions to GS' Short Duration List
Should You Sell Maravai LifeSciences (MRVI)?
Bio-Techne and Qiagen Had the Biggest Increase in Short Interest Levels Last Month - Baird
Maravai LifeSciences Announces March 2024 Investor Conference Schedule
SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the
Analysis
Price Target
No Data
